
Charles Bernstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1457007/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease. Gut, 2023, 72, 802-804.	12.1	12
2	Use of thiopurines in inflammatory bowel disease: an update. Intestinal Research, 2022, 20, 11-30.	2.6	38
3	COVIDâ€19–related personal product shortages are associated with psychological distress in people living with gastrointestinal disorders: A crossâ€sectional survey. Neurogastroenterology and Motility, 2022, 34, e14198.	3.0	9
4	Factors Associated With Social Participation in Persons Living With Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 2022, 5, 59-67.	0.3	2
5	What Is a Flare? The Manitoba Living With IBD Study. Inflammatory Bowel Diseases, 2022, 28, 862-869.	1.9	5
6	Exploring the Relationship Between Self-Isolation and Distress Among People with Gastrointestinal Disorders During the COVID-19 Pandemic. Journal of Clinical Psychology in Medical Settings, 2022, 29, 654-665.	1.4	6
7	Insight into Inflammatory Bowel Disease Pathogenesis: Is the Answer Blowing in the Wind?. Inflammatory Bowel Diseases, 2022, 28, 486-491.	1.9	7
8	Extending the Common Sense Model to Explore the Impact of the Fear of COVID-19 on Quality of Life in an International Inflammatory Bowel Disease Cohort. Journal of Clinical Psychology in Medical Settings, 2022, 29, 678-688.	1.4	8
9	Childhood Maltreatment and Psychiatric Comorbidity in Immune-Mediated Inflammatory Disorders. Psychosomatic Medicine, 2022, 84, 10-19.	2.0	15
10	IBD Disability Index Is Associated With Both Direct and Indirect Costs of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 1189-1197.	1.9	3
11	Colorectal Cancer Screening in Inflammatory Bowel Diseases—Can Characterization of GI Microbiome Signatures Enhance Neoplasia Detection?. Gastroenterology, 2022, 162, 1409-1423.e1.	1.3	10
12	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. Neurology, 2022, 98, .	1.1	15
13	Functional brain rewiring and altered cortical stability in ulcerative colitis. Molecular Psychiatry, 2022, 27, 1792-1804.	7.9	11
14	Pregnancy and Live Birth Rates Over Time in Women With Inflammatory Bowel Disease: A Population-Based Cohort Study. Journal of the Canadian Association of Gastroenterology, 2022, 5, 184-191.	0.3	1
15	P701 Compositional and functional alterations of the gut microbiome are associated with impaired intestinal permeability in healthy relatives of patients with Crohn's disease. Journal of Crohn's and Colitis, 2022, 16, i597-i598.	1.3	0
16	Polygenic risk and causal inference of psychiatric comorbidity in inflammatory bowel disease among patients with European ancestry. Journal of Translational Medicine, 2022, 20, 43.	4.4	1
17	The association of efficacy, optimism, uncertainty and health anxiety with inflammatory bowel disease activity. Journal of Psychosomatic Research, 2022, 154, 110719.	2.6	4
18	Selfâ€reported flares among people living with inflammatory bowel disease are associated with stress and worry but not associated with recent diet changes: The Manitoba Living with IBD Study. Journal of Parenteral and Enteral Nutrition, 2022, 46, 1686-1698.	2.6	5

#	Article	IF	CITATIONS
19	Associations between courses of posttraumatic stress disorder and physical health conditions among Canadian military personnel. Journal of Anxiety Disorders, 2022, 87, 102543.	3.2	4
20	Editorial: some of the obstacles in managing mood disorders in <scp>IBD</scp> . Alimentary Pharmacology and Therapeutics, 2022, 55, 1054-1055.	3.7	0
21	Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. Multiple Sclerosis Journal, 2022, 28, 1819-1824.	3.0	2
22	Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 2607-2618.e14.	4.4	13
23	Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 874724.	2.4	4
24	Depressive symptom trajectories and polygenic risk scores in individuals with an immune-mediated inflammatory disease. General Hospital Psychiatry, 2022, 77, 21-28.	2.4	5
25	Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response. Journal of the Canadian Association of Gastroenterology, 2022, 5, 208-213.	0.3	6
26	Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. The Lancet Gastroenterology and Hepatology, 2022, 7, 666-678.	8.1	31
27	Brain structure and function changes in inflammatory bowel disease. NeuroImage Reports, 2022, 2, 100097.	1.0	2
28	The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. Multiple Sclerosis and Related Disorders, 2022, 63, 103829.	2.0	8
29	Effects of Vascular Comorbidity on Cognition in Multiple Sclerosis Are Partially Mediated by Changes in Brain Structure. Frontiers in Neurology, 2022, 13, .	2.4	11
30	Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 2064-2071.e1.	4.4	8
31	Effect of mood and anxiety disorders on health care utilization in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1411-1420.	3.0	6
32	Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders. Multiple Sclerosis Journal, 2021, 27, 1284-1292.	3.0	13
33	Rationale and Methodology of the 2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS): A 16-year Follow-up Survey: Raison D'A³tre Et Méthodologie De L'enquê De Suivi Sur La Santé Mentale Des Membres Des Forces Armées Canadiennes Et Des Anciens Combattants. 2018 (ESSMFACM). Canadian Journal of Psychiatry. 2021. 66. 942-950.	te 1.9	12
34	An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI. Clinical Gastroenterology and Hepatology, 2021, 19, 2524-2531.	4.4	5
35	Does conventional early life academic excellence predict later life scientific discovery? An assessment of the lives of great medical innovators. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 381-389.	0.5	0
36	Association Between Change in Inflammatory Aspects of Diet and Change in IBD-related Inflammation and Symptoms Over 1 Year: The Manitoba Living With IBD Study. Inflammatory Bowel Diseases, 2021, 27, 190-202.	1.9	13

#	Article	IF	CITATIONS
37	Utility of the MARS-5 in Assessing Medication Adherence in IBD. Inflammatory Bowel Diseases, 2021, 27, 317-324.	1.9	12
38	Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. Gut, 2021, 70, 499-510.	12.1	127
39	Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 58-64.	1.9	12
40	Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. Inflammatory Bowel Diseases, 2021, 27, 836-847.	1.9	21
41	Impact of Psychiatric Comorbidity on Health Care Use in Rheumatoid Arthritis: A Populationâ€Based Study. Arthritis Care and Research, 2021, 73, 90-99.	3.4	6
42	Anxiety and Depression Leads to Anti–Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 1200-1208.e1.	4.4	18
43	AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. Gastroenterology, 2021, 160, 445-451.	1.3	33
44	Gastroenterologist Consultation Is Uncommon but Associated with Improved Care Among IBD Patients Presenting to Emergency Departments in Winnipeg Hospitals. Journal of the Canadian Association of Gastroenterology, 2021, 4, 57-64.	0.3	2
45	A Rare Complication of Pancreatitis. Gastroenterology, 2021, 160, 1479-1480.	1.3	2
46	Neuregulin-1 beta 1 is implicated in pathogenesis of multiple sclerosis. Brain, 2021, 144, 162-185.	7.6	11
47	What Are the Most Challenging Aspects of Inflammatory Bowel Disease? An International Survey of Gastroenterologists Comparing Developed and Developing Countries. Inflammatory Intestinal Diseases, 2021, 6, 78-86.	1.9	6
48	A 49-Year-Old Male With Fever and Abdominal Pain. Clinical Infectious Diseases, 2021, 73, 2140-2143.	5.8	2
49	Altered brain structural connectivity in patients with longstanding gut inflammation is correlated with psychological symptoms and disease duration. NeuroImage: Clinical, 2021, 30, 102613.	2.7	19
50	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. Journal of the Canadian Association of Gastroenterology, 2021, 4, S10-S19.	0.3	2
51	The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time. Inflammatory Bowel Diseases, 2021, 27, 1285-1293.	1.9	64
52	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. Journal of the Canadian Association of Gastroenterology, 2021, 4, S34-S39.	0.3	2
53	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S20-S26.	0.3	0
54	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S40-S45.	0.3	4

#	Article	IF	CITATIONS
55	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. Journal of the Canadian Association of Gastroenterology, 2021, 4, S61-S67.	0.3	7
56	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S1-S9.	0.3	5
57	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S27-S33.	0.3	3
58	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. Journal of the Canadian Association of Gastroenterology, 2021, 4, S46-S53.	0.3	9
59	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations. Journal of the Canadian Association of Gastroenterology, 2021, 4, S54-S60.	0.3	9
60	Pancreastatin Reduces Alternatively Activated Macrophages, Disrupts the Epithelial Homeostasis and Aggravates Colonic Inflammation. A Descriptive Analysis. Biomedicines, 2021, 9, 134.	3.2	3
61	Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study. American Journal of Gastroenterology, 2021, 116, 1476-1484.	0.4	14
62	Lifetime Prevalence and Comorbidity of Mental Disorders in the Two-wave 2002–2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS): Prévalence et Comorbidité de Durée de vie Des Troubles Mentaux Dans l'Enquête de Suivi Sur la Santé Mentale Auprès des Membres des Forces Armées Canadiennes et Des ex-Militaires (ESSMFACM) en Deux Cycles de 2002 Ã 2018. Canadian Journal of Psychiatry, 2021, 66, 070674372110006.	1.9	15
63	Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. American Journal of Gastroenterology, 2021, 116, 1284-1293.	0.4	12
64	Dietary gluten avoidance in Canada: a cross-sectional study using survey data. CMAJ Open, 2021, 9, E317-E323.	2.4	4
65	Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study. CMAJ Open, 2021, 9, E510-E521.	2.4	10
66	Genetic predictors of gene expression associated with psychiatric comorbidity in patients with inflammatory bowel disease – A pilot study. Genomics, 2021, 113, 919-932.	2.9	4
67	Psychiatric comorbidity in immuneâ€mediated inflammatory diseases. World Psychiatry, 2021, 20, 298-299.	10.4	14
68	The association between childhood maltreatment and pain catastrophizing in individuals with immune-mediated inflammatory diseases. Journal of Psychosomatic Research, 2021, 145, 110479.	2.6	11
69	Increased Incidence of Inflammatory Bowel Disease After Hirschsprung Disease: A Population-based Cohort Study. Journal of Pediatrics, 2021, 233, 98-104.e2.	1.8	8
70	Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children: A Population-Based Matched Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 2031-2040.	1.3	20
71	Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. The Lancet Gastroenterology and Hepatology, 2021, 6, 482-497.	8.1	28
72	Comorbidity before and after a diagnosis of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 637-651.	3.7	25

#	Article	IF	CITATIONS
73	Continued 5ASA use after initiation of antiâ€TNF or immunomodulator confers no benefit in IBD: a populationâ€based study. Alimentary Pharmacology and Therapeutics, 2021, 54, 814-832.	3.7	7
74	Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice. Intestinal Research, 2021, 19, 332-340.	2.6	8
75	Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease. PLoS ONE, 2021, 16, e0249809.	2.5	6
76	Editorial: 5â€ASA in IBD patients on biologics—'stop or continue'? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 845-845.	3.7	0
77	The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders: A protocol of an international collaborative study. Journal of Psychosomatic Research, 2021, 148, 110561.	2.6	7
78	The 5-year pre- and post-hospitalization treated prevalence of mental disorders and psychotropic medication use in critically ill patients: a Canadian population-based study. Intensive Care Medicine, 2021, 47, 1450-1461.	8.2	15
79	Higher Framingham Risk Scores are associated with greater loss of brain volume over time in multiple sclerosis and Related Disorders, 2021, 54, 103088.	2.0	10
80	A Unique Case of Esophagitis in an Immunocompromised Patient. Gastroenterology, 2021, 161, e8-e9.	1.3	1
81	Prevalence and Risk Factors of Substance Use Disorder in Rheumatoid Arthritis. ACR Open Rheumatology, 2021, 3, 889-896.	2.1	3
82	The complex relationship between diet, symptoms, and intestinal inflammation in persons with inflammatory bowel disease: The Manitoba Living With IBD Study. Journal of Parenteral and Enteral Nutrition, 2021, , .	2.6	4
83	Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. The Lancet Gastroenterology and Hepatology, 2021, 6, 826-849.	8.1	69
84	Psychological Comorbidity and Intervention in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2021, 55, 30-35.	2.2	7
85	Prevalence of Gastroduodenal Polyps in Children With Familial Adenomatous Polyposis. Journal of the Canadian Association of Gastroenterology, 2021, 4, e101-e109.	0.3	1
86	Microbiome-Mediated Immune Signaling in Inflammatory Bowel Disease and Colorectal Cancer: Support From Meta-omics Data. Frontiers in Cell and Developmental Biology, 2021, 9, 716604.	3.7	9
87	Brain structure and function changes in ulcerative colitis. NeuroImage Reports, 2021, 1, 100064.	1.0	4
88	Impact of intrarectal chromofungin treatment on dendritic cells-related markers in different immune compartments in colonic inflammatory conditions. World Journal of Gastroenterology, 2021, 27, 8138-8155.	3.3	4
89	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Annals of Clinical and Translational Neurology, 2021, 8, 2252-2269.	3.7	34
90	Trends in paediatric inflammatory bowel diseaseâ€attributable direct costs: a populationâ€based analysis. Alimentary Pharmacology and Therapeutics, 2021, 53, 1201-1208.	3.7	6

#	Article	IF	CITATIONS
91	Editorial: trends in paediatric inflammatory bowel disease attributable direct costs—authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 1234-1235.	3.7	0
92	Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study. Inflammatory Bowel Diseases, 2020, 26, 134-138.	1.9	10
93	A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD. Inflammatory Bowel Diseases, 2020, 26, 150-157.	1.9	4
94	Is Antibiotic Use a Cause of IBD Worldwide?. Inflammatory Bowel Diseases, 2020, 26, 448-449.	1.9	4
95	Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut, 2020, 69, 274-282.	12.1	145
96	Copy number variation-based gene set analysis reveals cytokine signalling pathways associated with psychiatric comorbidity in patients with inflammatory bowel disease. Genomics, 2020, 112, 683-693.	2.9	8
97	Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Rheumatoid Arthritis. Arthritis Care and Research, 2020, 72, 1130-1139.	3.4	63
98	Integrated Care Models: Optimizing Adult Ambulatory Care in Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 2020, 3, 44-53.	0.3	14
99	The Cost of Use of the Emergency Department by Persons With Inflammatory Bowel Disease Living in a Canadian Health Region: A Retrospective Population-Based Study. Journal of the Canadian Association of Gastroenterology, 2020, 3, 135-140.	0.3	3
100	The multiple sclerosis gut microbiota: A systematic review. Multiple Sclerosis and Related Disorders, 2020, 37, 101427.	2.0	102
101	Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse. Inflammatory Bowel Diseases, 2020, 26, 1401-1406.	1.9	16
102	Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population–Based Analysis. American Journal of Gastroenterology, 2020, 115, 128-137.	0.4	39
103	Most Patients With Celiac Disease on Gluten-Free Diets Consume Measurable Amounts of Gluten. Gastroenterology, 2020, 158, 1497-1499.e1.	1.3	65
104	IBD in India. Journal of Clinical Gastroenterology, 2020, 54, 725-732.	2.2	12
105	ldentifying Patients With Inflammatory Bowel Diseases atÂHigh vs Low Risk of Complications. Clinical Gastroenterology and Hepatology, 2020, 18, 1261-1267.	4.4	22
106	Social phobia in immune-mediated inflammatory diseases. Journal of Psychosomatic Research, 2020, 128, 109890.	2.6	6
107	A258 ASSOCIATION BETWEEN SYMPTOMS AND INFLAMMATORY BOWEL DISEASE ACTIVITY USING INFLAMMATORY BOWEL DISEASE SYMPTOM INVENTORY – A RETROSPECTIVE ANALYSIS FROM THE MANITOBA LIVING WITH IBD STUDY. Journal of the Canadian Association of Gastroenterology, 2020, 3, 135-136.	0.3	1
108	Assessment of Inter-Laboratory Variation in the Characterization and Analysis of the Mucosal Microbiota in Crohn's Disease and Ulcerative Colitis. Frontiers in Microbiology, 2020, 11, 2028.	3.5	8

#	Article	IF	CITATIONS
109	COVID-19 Pandemic: Which IBD Patients Need to Be Scoped—Who Gets Scoped Now, Who Can Wait, and how to Resume to Normal. Journal of Crohn's and Colitis, 2020, 14, S791-S797.	1.3	14
110	Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy. Crohn's & Colitis 360, 2020, 2, .	1.1	8
111	The 5-Year Incidence of Mental Disorders in a Population-Based ICU Survivor Cohort. Critical Care Medicine, 2020, 48, e675-e683.	0.9	18
112	Denosumab Regulates Gut Microbiota Composition and Cytokines in Dinitrobenzene Sulfonic Acid (DNBS)-Experimental Colitis. Frontiers in Microbiology, 2020, 11, 1405.	3.5	8
113	Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease. Frontiers in Pediatrics, 2020, 8, 400.	1.9	10
114	Time trends and predictors of laboratory-confirmed recurrent and severe <i>Clostridioides difficile</i> infections in Manitoba: a population-based study. CMAJ Open, 2020, 8, E737-E746.	2.4	1
115	Exposure sources, amounts and time course of gluten ingestion and excretion in patients with coeliac disease on a glutenâ€free diet. Alimentary Pharmacology and Therapeutics, 2020, 52, 1469-1479.	3.7	42
116	The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study. Inflammatory Bowel Diseases, 2020, 27, 1462-1474.	1.9	10
117	Increased Intestinal Permeability Is Associated With Later Development of Crohn's Disease. Gastroenterology, 2020, 159, 2092-2100.e5.	1.3	156
118	Interdependence between Chromogranin-A, Alternatively Activated Macrophages, Tight Junction Proteins and the Epithelial Functions. A Human and In-Vivo/In-Vitro Descriptive Study. International Journal of Molecular Sciences, 2020, 21, 7976.	4.1	8
119	Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection. Journal of Infection, 2020, 81, 758-765.	3.3	9
120	Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis. Drug Safety, 2020, 43, 1255-1266.	3.2	5
121	Ulcerative colitis. Nature Reviews Disease Primers, 2020, 6, 74.	30.5	678
122	Nutritional implications of dietary gluten avoidance among Canadians: results from the 2015 Canadian Community Health Survey. British Journal of Nutrition, 2020, 126, 1-9.	2.3	3
123	IMAGINE Network's Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome. BMJ Open, 2020, 10, e041733.	1.9	5
124	Patterns of care for inflammatory bowel disease in China during the COVID-19 pandemic. The Lancet Gastroenterology and Hepatology, 2020, 5, 632-634.	8.1	14
125	Review article: bugs, inflammation and mood—a microbiotaâ€based approach to psychiatric symptoms in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2020, 52, 247-266.	3.7	26
126	Overcoming Workplace Disability in IBD Patients: An Observational Study. Inflammatory Intestinal Diseases, 2020, 5, 84-92.	1.9	6

#	Article	IF	CITATIONS
127	Development of the Dietitian Integrated Evaluation Tool for Gluten-free Diets (DIET-GFD). Nutrition, 2020, 78, 110819.	2.4	5
128	Brain Resting-State Network Alterations Associated With Crohn's Disease. Frontiers in Neurology, 2020, 11, 48.	2.4	33
129	Long-term Cancer Risk in Patients With Pediatric-Onset Inflammatory Bowel Diseases in the Canadian Population. Gastroenterology, 2020, 159, 386-387.	1.3	10
130	Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. Journal of Crohn's and Colitis, 2020, 14, 1354-1363.	1.3	38
131	Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. Journal of Clinical Epidemiology, 2020, 122, 115-128.e1.	5.0	113
132	Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. The Lancet Gastroenterology and Hepatology, 2020, 5, 393-405.	8.1	78
133	Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review. Crohn's & Colitis 360, 2020, 2, otz053.	1.1	8
134	New Biomarkers for Crohn's Disease. Gastroenterology, 2020, 159, 30-32.	1.3	1
135	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology, 2020, 159, 6-13.e6.	1.3	185
136	The Use of Capsule Endoscopy For Diagnosis of Iron Deficiency Anemia: A Retrospective Analysis. Journal of Clinical Gastroenterology, 2020, 54, 452-458.	2.2	10
137	Performance of Regression-Based Norms for Cognitive Functioning of Persons With Multiple Sclerosis in an Independent Sample. Frontiers in Neurology, 2020, 11, 621010.	2.4	9
138	Can individuals with celiac disease identify gluten-free foods correctly?. Clinical Nutrition ESPEN, 2020, 36, 82-90.	1.2	15
139	Machine-learning models for depression and anxiety in individuals with immune-mediated inflammatory disease. Journal of Psychosomatic Research, 2020, 134, 110126.	2.6	20
140	Social Determinants of Outcomes in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2020, 115, 2036-2046.	0.4	24
141	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2020, 3, 249-256.	0.3	5
142	Dose Augmentation of Tumor Necrosis Factor Inhibitors is Frequently Performed in Persons With Inflammatory Bowel Disease in the Absence of Objective Evidence of Active Inflammation. Journal of Clinical Gastroenterology, 2020, Publish Ahead of Print, 602-608.	2.2	1
143	Herpes Zoster Infection and Herpes Zoster Vaccination in a Population-Based Sample of Persons With IBD: Is There Still an Unmet Need?. Inflammatory Bowel Diseases, 2019, 25, 532-540.	1.9	18
144	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Inflammatory Bowel Diseases, 2019, 25, 1-13.	1.9	73

#	Article	IF	CITATIONS
145	Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 360-368.	1.9	166
146	Association Between IBD Disability and Reduced Work Productivity (Presenteeism): A Population-Based Study in Manitoba, Canada. Inflammatory Bowel Diseases, 2019, 25, 352-359.	1.9	24
147	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1680-1713.	4.4	32
148	Activating Killer-cell Immunoglobulin-like Receptor genes confer risk for Crohn's disease in children and adults of the Western European descent: Findings based on case-control studies. PLoS ONE, 2019, 14, e0217767.	2.5	3
149	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2019, 2, e1-e34.	0.3	32
150	Genome-wide copy number variant data for inflammatory bowel disease in a caucasian population. Data in Brief, 2019, 25, 104203.	1.0	0
151	Direct cost of health care for individuals with community associated Clostridium difficile infections: A population-based cohort study. PLoS ONE, 2019, 14, e0224609.	2.5	6
152	Geographical Variation and Factors Associated With Inflammatory Bowel Disease in a Central Canadian Province. Inflammatory Bowel Diseases, 2019, 26, 581-590.	1.9	8
153	Sorting Through the Risks and Benefits of Thiopurine Therapy for Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 2171-2172.	4.4	6
154	Reply. Gastroenterology, 2019, 157, 1443-1444.	1.3	0
155	The Gut Microbiome as a Target for IBD Treatment: Are We There Yet?. Current Treatment Options in Gastroenterology, 2019, 17, 115-126.	0.8	90
156	Health Care Indicators of Moderate to Severe IBD and Subsequent IBD-Related Disability: A Longitudinal Study. Inflammatory Bowel Diseases, 2019, 25, 1996-2005.	1.9	8
157	The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care. Journal of the Canadian Association of Gastroenterology, 2019, 2, S34-S41.	0.3	31
158	The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1718-1728.	1.9	31
159	Semaphorin 3E regulates apoptosis in the intestinal epithelium during the development of colitis. Biochemical Pharmacology, 2019, 166, 264-273.	4.4	17
160	Genome-wide analysis identifies rare copy number variations associated with inflammatory bowel disease. PLoS ONE, 2019, 14, e0217846.	2.5	16
161	Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis. Patient Education and Counseling, 2019, 102, 1722-1729.	2.2	12
162	The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD. Journal of the Canadian Association of Gastroenterology, 2019, 2, S73-S80.	0.3	57

#	Article	IF	CITATIONS
163	Challenges in IBD Research: Environmental Triggers. Inflammatory Bowel Diseases, 2019, 25, S13-S23.	1.9	62
164	The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Journal of the Canadian Association of Gastroenterology, 2019, 2, S17-S33.	0.3	63
165	Events Within the First Year of Life, but Not the Neonatal Period, Affect Risk for Later Development of Inflammatory Bowel Diseases. Gastroenterology, 2019, 156, 2190-2197.e10.	1.3	53
166	A102 REGULATION OF ENDPLASMIC RETICULUM STRESS/P53-APOPTITIC PATHWAYS BY CHROMOFUNGIN IN THE CONTEXT OF EXPERIEMENTAL COLITIS. Journal of the Canadian Association of Gastroenterology, 2019, 2, 203-204.	0.3	0
167	The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1674-1680.	1.9	73
168	Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology, 2019, 156, 1345-1353.e4.	1.3	273
169	A43 CHROMOGRANIN-A REGULATES INDIRECTLY EPITHELIAL REPAIR VIA THE ALTERNATIVELY ACTIVATED MACROPHAGES IN COLONIC INFLAMMATORY STATES. Journal of the Canadian Association of Gastroenterology, 2019, 2, 86-87.	0.3	1
170	Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clinical Gastroenterology and Hepatology, 2019, 17, 1788-1798.e2.	4.4	23
171	The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors. Journal of the Canadian Association of Gastroenterology, 2019, 2, S68-S72.	0.3	29
172	The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology. Journal of the Canadian Association of Gastroenterology, 2019, 2, S6-S16.	0.3	95
173	The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application. Inflammatory Bowel Diseases, 2019, 25, 1277-1290.	1.9	27
174	The Relationship Between Adverse Childhood Experiences and Health Care Use in the Manitoba IBD Cohort Study. Inflammatory Bowel Diseases, 2019, 25, 1700-1710.	1.9	13
175	Semaphorinâ€3E attenuates intestinal inflammation through the regulation of the communication between splenic CD11C ⁺ and CD4 ⁺ CD25 ^{â^'} Tâ€cells. British Journal of Pharmacology, 2019, 176, 1235-1250.	5.4	14
176	The Gut Microbiome in Inflammatory Bowel Disease: Lessons Learned From Other Immune-Mediated Inflammatory Diseases. American Journal of Gastroenterology, 2019, 114, 1051-1070.	0.4	53
177	The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis Canada. Journal of the Canadian Association of Gastroenterology, 2019, 2, S1-S5.	0.3	46
178	Trends and Predictors of Clostridium difficile Infection among Children: A Canadian Population-Based Study. Journal of Pediatrics, 2019, 206, 20-25.	1.8	13
179	Reply to Letter to Editor of Dr. Elia. Inflammatory Bowel Diseases, 2019, 25, e9-e9.	1.9	0
180	The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD. Journal of the Canadian Association of Gastroenterology, 2019, 2, S49-S67.	0.3	70

#	Article	IF	CITATIONS
181	Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. Neurology, 2019, 92, .	1.1	79
182	Diabetes and anxiety adversely affect cognition in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 164-170.	2.0	33
183	Family History Associates With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1807-1813.e1.	4.4	43
184	Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiology and Psychiatric Sciences, 2019, 28, 333-342.	3.9	91
185	Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study. Gut, 2019, 68, 615-622.	12.1	27
186	Inflammatory bowel disease patient profiles are related to specific information needs: A nationwide survey. World Journal of Gastroenterology, 2019, 25, 4246-4260.	3.3	18
187	A171 DEVELOPMENT AND VALIDATION OF THE DIETITIAN INTEGRATED EVALUATION TOOL FOR GLUTEN-FREE DIETS (DIET-GFD). Journal of the Canadian Association of Gastroenterology, 2018, 1, 255-255.	0.3	0
188	Chromogranin-A and its derived peptides and their pharmacological effects during intestinal inflammation. Biochemical Pharmacology, 2018, 152, 315-326.	4.4	32
189	Reply. Gastroenterology, 2018, 154, 256-257.	1.3	0
190	Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials. BMJ Open, 2018, 8, e019240.	1.9	70
191	The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 1867-1875.	1.9	84
192	Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis. Arthritis Care and Research, 2018, 70, 970-978.	3.4	100
193	Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease. General Hospital Psychiatry, 2018, 51, 71-78.	2.4	19
194	The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis and Related Disorders, 2018, 20, 9-15.	2.0	113
195	Chromogranin-A Regulates Macrophage Function and the Apoptotic Pathway in Murine DSS colitis. Journal of Molecular Medicine, 2018, 96, 183-198.	3.9	28
196	Factors Associated with Anxiety About Colonoscopy: The Preparation, the Procedure, and the Anticipated Findings. Digestive Diseases and Sciences, 2018, 63, 610-618.	2.3	47
197	Past Time for Doctors to Lessen their Dependence on Corticosteroids in the Treatment of IBD. American Journal of Gastroenterology, 2018, 113, 418-420.	0.4	4
198	Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 1641-1648.	1.9	21

#	Article	IF	CITATIONS
199	Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients. Inflammatory Bowel Diseases, 2018, 24, 766-774.	1.9	22
200	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	12.1	108
201	Putting Evidence into Practice: IBD Surveillance, Chromoendoscopy and Future Directions. American Journal of Gastroenterology, 2018, 113, 313-316.	0.4	8
202	Environmental triggers in IBD: a review of progress and evidence. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 39-49.	17.8	573
203	Information Experiences, Needs, and Preferences of Colonoscopy Patients: A Pre-Colonoscopy Survey. American Journal of Gastroenterology, 2018, 113, S291-S292.	0.4	0
204	Addressing Mental Health in Persons with IBD. Journal of the Canadian Association of Gastroenterology, 2018, 1, 97-98.	0.3	8
205	Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. Clinical Epidemiology, 2018, Volume 10, 1613-1626.	3.0	48
206	A137 PANCREASTATIN (PTS) EXACERBATES COLONIC INFLAMMATION. Journal of the Canadian Association of Gastroenterology, 2018, 1, 237-238.	0.3	1
207	A comparative study of the gut microbiota in immune-mediated inflammatory diseases—does a common dysbiosis exist?. Microbiome, 2018, 6, 221.	11.1	303
208	Catestatin Regulates Epithelial Cell Dynamics to Improve Intestinal Inflammation. Vaccines, 2018, 6, 67.	4.4	23
209	Sex-Based Differences in Incidence of Inflammatory Bowel Diseases—Pooled Analysis of Population-Based Studies From Western Countries. Gastroenterology, 2018, 155, 1079-1089.e3.	1.3	155
210	Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 2018, 26, 124-156.	2.0	33
211	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Journal of the Canadian Association of Gastroenterology, 2018, 1, 141-154.	0.3	10
212	Reversing Ongoing Chronic Intestinal Inflammation and Fibrosis by Sustained Block of IL-12 and IL-23 Using a Vaccine in Mice. Inflammatory Bowel Diseases, 2018, 24, 1941-1952.	1.9	19
213	A1 SEMAPHORIN3E (SEMA3E) REGULATES INTESTINAL INFLAMMATION THROUGH THE MODULATION OF DENDRITIC CELLS FUNCTIONS. Journal of the Canadian Association of Gastroenterology, 2018, 1, 2-2.	0.3	0
214	Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. General Hospital Psychiatry, 2018, 53, 65-72.	2.4	73
215	Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD. American Journal of Gastroenterology, 2018, 113, 1206-1216.	0.4	7
216	Factors associated with perceived need for mental health care in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 179-185.	2.0	14

#	Article	IF	CITATIONS
217	A29 THE RISING PREVALENCE OF INFLAMMATORY BOWEL DISEASE IN CANADA: ANALYZING THE PAST TO PREDICT THE FUTURE. Journal of the Canadian Association of Gastroenterology, 2018, 1, 47-48.	0.3	8
218	Sa1073 - Time Trends of Laboratory Confirmed Clostridium Difficile Infections in an Entire Province Suggest an Increasing Shift to Community Acquired Infections and Younger Age of Acquiring Infections. Gastroenterology, 2018, 154, S-230-S-231.	1.3	1
219	Mo1125 THE USE OF CAPSULE ENDOSCOPY FOR DIAGNOSIS OF IRON DEFICIENCY ANEMIA- A RETROSPECTIVE ANALYSIS. Gastrointestinal Endoscopy, 2018, 87, AB408.	1.0	0
220	Predictors of patient reluctance to wake early in the morning for bowel preparation for colonoscopy: a precolonoscopy survey in city-wide practice. Endoscopy International Open, 2018, 06, E706-E713.	1.8	7
221	The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases. PLoS ONE, 2018, 13, e0198975.	2.5	58
222	A Fungal World: Could the Gut Mycobiome Be Involved in Neurological Disease?. Frontiers in Microbiology, 2018, 9, 3249.	3.5	80
223	Living With Inflammatory Bowel Disease: Protocol for a Longitudinal Study of Factors Associated With Symptom Exacerbations. JMIR Research Protocols, 2018, 7, e11317.	1.0	11
224	Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study. JMIR Research Protocols, 2018, 7, e15.	1.0	38
225	Clinical Practice Guidelines for the Use of Video CapsuleÂEndoscopy. Gastroenterology, 2017, 152, 497-514.	1.3	306
226	Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 1061-1070.e1.	4.4	32
227	Appropriateness of reference genes for normalizing messenger RNA in mouse 2,4-dinitrobenzene sulfonic acid (DNBS)-induced colitis using quantitative real time PCR. Scientific Reports, 2017, 7, 42427.	3.3	42
228	Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases. American Journal of Gastroenterology, 2017, 112, 1120-1134.	0.4	241
229	Coping with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1247-1256.	1.9	7
230	Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease. Gastroenterology, 2017, 153, 430-438.e2.	1.3	109
231	Hospitalization is associated with subsequent disability in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 14, 23-28.	2.0	7
232	Editorial: the impact of the placebo effect in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1471-1472.	3.7	4
233	Markedly increased incidence of critical illness in adults with Type 1 diabetes. Diabetic Medicine, 2017, 34, 1414-1420.	2.3	4
234	Increased Incidence of Critical Illness in Psoriasis. Journal of Cutaneous Medicine and Surgery, 2017, 21, 395-400.	1.2	1

#	Article	IF	CITATIONS
235	Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons With Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2017, 23, 425-434.	0.9	75
236	Workplace Accommodation for Persons With IBD: What Is Needed and What Is Accessed. Clinical Gastroenterology and Hepatology, 2017, 15, 1589-1595.e4.	4.4	11
237	Upper Versus Lower Endoscopy in the Diagnosis of Graft-Versus-Host Disease. Journal of Clinical Gastroenterology, 2017, 51, 701-706.	2.2	9
238	Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah. Digestive Diseases and Sciences, 2017, 62, 2126-2132.	2.3	42
239	The Brain-Gut Axis and Stress in Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2017, 46, 839-846.	2.2	62
240	The SLC2A14 gene, encoding the novel glucose/dehydroascorbate transporter GLUT14, is associated with inflammatory bowel disease. American Journal of Clinical Nutrition, 2017, 106, 1508-1513.	4.7	22
241	Review article: changes in the epidemiology of inflammatory bowel disease—clues for aetiology. Alimentary Pharmacology and Therapeutics, 2017, 46, 911-919.	3.7	75
242	Large Registry Epidemiology in IBD. Inflammatory Bowel Diseases, 2017, 23, 1941-1949.	1.9	10
243	Chromofungin (CHR: CHGA47-66) is downregulated in persons with active ulcerative colitis and suppresses pro-inflammatory macrophage function through the inhibition of NF-I®B signaling. Biochemical Pharmacology, 2017, 145, 102-113.	4.4	36
244	No Increase in Immunomodulator Use in Combination with Anti-TNF Therapy in the Post Sonic ERA. Gastroenterology, 2017, 152, S400.	1.3	1
245	Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. Journal of Psychosomatic Research, 2017, 101, 17-23.	2.6	131
246	Risk of Surgery and Mortality in Elderly-onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 218-223.	1.9	77
247	Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD. Inflammatory Bowel Diseases, 2017, 23, 409-420.	1.9	34
248	Maternal Infections That Would Warrant Antibiotic Use Antepartum or Peripartum Are Not a Risk Factor for the Development of IBD. Inflammatory Bowel Diseases, 2017, 23, 635-640.	1.9	11
249	Health Care Services in IBD. Inflammatory Bowel Diseases, 2017, 23, 1461-1469.	1.9	15
250	Molecular basis for increased susceptibility of Indigenous North Americans to seropositive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1915-1923.	0.9	36
251	Yes, We Are Still Talking about Cylosporin vs. Infliximab in Steroid Resistant Acute Severe Ulcerative Colitis. American Journal of Gastroenterology, 2017, 112, 1719-1721.	0.4	6
252	Gut Microbiome in Inflammatory Bowel Disease and Other Chronic Immune-Mediated Inflammatory Diseases. Inflammatory Intestinal Diseases, 2017, 2, 116-123.	1.9	71

#	Article	IF	CITATIONS
253	Symptoms of Functional Intestinal Disorders Are Common in Patients with Celiac Disease Following Transition to a Gluten-Free Diet. Digestive Diseases and Sciences, 2017, 62, 2449-2454.	2.3	27
254	Education, Employment, Income, and Marital Status Among Adults Diagnosed With Inflammatory Bowel Diseases During Childhood or Adolescence. Clinical Gastroenterology and Hepatology, 2017, 15, 518-524.	4.4	20
255	Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. BMC Research Notes, 2017, 10, 619.	1.4	38
256	Reactivation of Intestinal Inflammation Is Suppressed by Catestatin in a Murine Model of Colitis via M1 Macrophages and Not the Gut Microbiota. Frontiers in Immunology, 2017, 8, 985.	4.8	38
257	Chromofungin Ameliorates the Progression of Colitis by Regulating Alternatively Activated Macrophages. Frontiers in Immunology, 2017, 8, 1131.	4.8	41
258	Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease. Frontiers in Pediatrics, 2017, 5, 7.	1.9	14
259	Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice. World Journal of Gastroenterology, 2017, 23, 2995.	3.3	8
260	Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study. American Journal of Gastroenterology, 2017, 112, 1412-1422.	0.4	88
261	Hospital discharge abstracts have limited accuracy in identifying occurrence of Clostridium difficile infections among hospitalized individuals with inflammatory bowel disease: A population-based study. PLoS ONE, 2017, 12, e0171266.	2.5	8
262	Health care utilisation before and after intensive care unit admission in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2017, 35, 975-982.	0.8	2
263	Stability of Reference Genes for Messenger RNA Quantification by Real-Time PCR in Mouse Dextran Sodium Sulfate Experimental Colitis. PLoS ONE, 2016, 11, e0156289.	2.5	65
264	The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-6.	1.9	35
265	The Gut Microbiota in Immune-Mediated Inflammatory Diseases. Frontiers in Microbiology, 2016, 7, 1081.	3.5	315
266	Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease. BMC Research Notes, 2016, 9, 404.	1.4	40
267	Does everyone with inflammatory bowel disease need to be treated with combination therapy?. Current Opinion in Gastroenterology, 2016, 32, 287-293.	2.3	1
268	A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Alimentary Pharmacology and Therapeutics, 2016, 43, 974-984.	3.7	126
269	Estimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study. Journal of Crohn's and Colitis, 2016, 11, jjw201.	1.3	8
270	World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2016, 50, 803-818.	2.2	138

#	Article	IF	CITATIONS
271	Microbiome profiling of drinking water in relation to incidence of inflammatory bowel disease. Canadian Journal of Microbiology, 2016, 62, 781-793.	1.7	12
272	Psychological Stress and Depression: Risk Factors for IBD?. Digestive Diseases, 2016, 34, 58-63.	1.9	78
273	Performance of administrative case definitions for depression and anxiety in inflammatory bowel disease. Journal of Psychosomatic Research, 2016, 89, 107-113.	2.6	50
274	Understanding Work Experiences of People with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1688-1697.	1.9	24
275	Validating a Measure of Patient Self-efficacy in Disease Self-management Using a Population-based IBD Cohort. Inflammatory Bowel Diseases, 2016, 22, 2165-2172.	1.9	23
276	Predictors of Emergency Department Use by Persons with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2016, 22, 2907-2916.	1.9	39
277	Rates and Reasons for Nonuse of Prescription Medication for Inflammatory Bowel Disease in a Referral Clinic. Inflammatory Bowel Diseases, 2016, 22, 919-924.	1.9	11
278	Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments Within the Gastrointestinal Tract of Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2016, 22, 817-825.	1.9	114
279	A Population-based Study of Intensive Care Unit Admissions in Rheumatoid Arthritis. Journal of Rheumatology, 2016, 43, 26-33.	2.0	26
280	Cesarean Section Delivery Is Not a Risk Factor for Development of Inflammatory Bowel Disease: A Population-based Analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 50-57.	4.4	36
281	Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 5, 12-26.	2.0	133
282	What Are Adults With Inflammatory Bowel Disease (IBD) Eating? A Closer Look at the Dietary Habits of a Populationâ€Based Canadian IBD Cohort. Journal of Parenteral and Enteral Nutrition, 2016, 40, 405-411.	2.6	79
283	Characterization of Autoantigens Targeted by Anti-Citrullinated Protein Antibodies In Vivo: Prominent Role for Epitopes Derived from Histone 4 Proteins. PLoS ONE, 2016, 11, e0165501.	2.5	16
284	Screening Tools for Anxiety in People with Multiple Sclerosis. International Journal of MS Care, 2016, 18, 273-281.	1.0	24
285	Screening rates for colorectal cancer in Canada: a cross-sectional study. CMAJ Open, 2015, 3, E149-E157.	2.4	61
286	Predictors of ICU Admission and Outcomes 1 Year Post-Admission in Persons with IBD. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	4
287	The Potential Protective Role of Caveolin-1 in Intestinal Inflammation in TNBS-Induced Murine Colitis. PLoS ONE, 2015, 10, e0119004.	2.5	22
288	Human seroreactivity to gut microbiota antigens. Journal of Allergy and Clinical Immunology, 2015, 136, 1378-1386.e5.	2.9	48

#	Article	IF	CITATIONS
289	Patterns and Predictors of Long-term Nonuse of Medical Therapy Among Persons with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1615-1622.	1.9	13
290	Early Childhood Measles Vaccinations are not Associated with Paediatric IBD: A Population-based Analysis. Journal of Crohn's and Colitis, 2015, 9, 334-338.	1.3	11
291	Health care utilization before and after intensive care unit admission in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 296-303.	2.0	10
292	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. Gastroenterology, 2015, 148, 1035-1058.e3.	1.3	323
293	Health Care Use by a Population-Based Cohort of Children With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1302-1309.e3.	4.4	16
294	Spicing up the Treatment of Mild to Moderate Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2015, 13, 1450-1452.	4.4	6
295	Su1627 Unplanned Delayed Repeat ERCPs Are Common After ERCP for Benign Biliary Disease: a Population Based Study. Gastrointestinal Endoscopy, 2015, 81, AB357-AB358.	1.0	0
296	Academic Performance among Children with Inflammatory Bowel Disease: A Population-Based Study. Journal of Pediatrics, 2015, 166, 1128-1133.	1.8	29
297	Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut, 2015, 64, 1403-1411.	12.1	65
298	Treatment of IBD: Where We Are and Where We Are Going. American Journal of Gastroenterology, 2015, 110, 114-126.	0.4	176
299	Physician Global Assessments or Blood tests do not Predict Mucosal Disease Activity in Ulcerative Colitis. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 325-329.	1.9	24
300	Intensive care unit admission in multiple sclerosis. Neurology, 2014, 82, 2112-2119.	1.1	45
301	How can we improve models of care in inflammatory bowel disease? An international survey of IBD health professionals. Journal of Crohn's and Colitis, 2014, 8, 1668-1674.	1.3	47
302	Inflammatory Bowel Disease in Children of Manitoba. Journal of Pediatric Gastroenterology and Nutrition, 2014, 59, 763-766.	1.8	45
303	Risk factors and management of osteoporosis in inflammatory bowel disease. Current Opinion in Gastroenterology, 2014, 30, 168-174.	2.3	50
304	Prevalence of and Outcomes Associated with Corticosteroid Prescription in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 622-630.	1.9	49
305	Antibiotics, Probiotics and Prebiotics in IBD. Nestle Nutrition Institute Workshop Series, 2014, 79, 83-100.	0.1	28
306	Association Between Spring Season of Birth and Crohn's Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 277-282.	4.4	15

#	Article	IF	CITATIONS
307	Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease. Gastroenterology, 2014, 146, 681-688.e1.	1.3	294
308	Increased Incidence of Critical Illness Among Patients With Inflammatory Bowel Disease: A Population-Based Study. Clinical Gastroenterology and Hepatology, 2014, 12, 2063-2070.e4.	4.4	12
309	Younger Age at Diagnosis Is Associated With Panenteric, but Not More Aggressive, Crohn's Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 72-79.e1.	4.4	42
310	Catestatin decreases macrophage function in two mouse models of experimental colitis. Biochemical Pharmacology, 2014, 89, 386-398.	4.4	54
311	Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. Gastroenterology, 2014, 146, 835-848.e6.	1.3	277
312	What is the role for bisphosphonates in IBD?. Gut, 2014, 63, 1369-1370.	12.1	3
313	Single-nucleotide polymorphisms in SLC22A23 are associated with ulcerative colitis in a Canadian white cohort. American Journal of Clinical Nutrition, 2014, 100, 289-294.	4.7	12
314	Polymorphisms in the sodium-dependent ascorbate transporter gene SLC23A1 are associated with susceptibility to Crohn disease. American Journal of Clinical Nutrition, 2014, 99, 378-383.	4.7	38
315	Antibiotics Associated With Increased Risk of New-Onset Crohn's Disease But Not Ulcerative Colitis: A Meta-Analysis. American Journal of Gastroenterology, 2014, 109, 1728-1738.	0.4	292
316	The Prevalence and Predictors of Opioid Use in Inflammatory Bowel Disease: A Population-Based Analysis. American Journal of Gastroenterology, 2014, 109, 1613-1620.	0.4	106
317	Low Prevalence of Disability Among Patients With Inflammatory Bowel Diseases a Decade After Diagnosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1330-1337.e2.	4.4	40
318	Sa1201 Development of an IBD Symptom Self-Report Scale for Research and Clinical Application. Gastroenterology, 2014, 146, S-228-S-229.	1.3	2
319	Should Patients With Inflammatory Bowel Disease Take Vitamin D to Prevent Cancer?. Clinical Gastroenterology and Hepatology, 2014, 12, 828-830.	4.4	4
320	Trends in utilization of diagnostic and therapeutic ERCP and cholecystectomy over the past 25 years: a population-based study. Gastrointestinal Endoscopy, 2014, 79, 615-622.	1.0	57
321	Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States. Inflammatory Bowel Diseases, 2014, 20, 398-415.	1.9	33
322	Relative importance measures for reprioritization response shift. Quality of Life Research, 2013, 22, 695-703.	3.1	29
323	The role and potential therapeutic application of myeloid-derived suppressor cells in TNBS-induced colitis. Journal of Leukocyte Biology, 2013, 94, 803-811.	3.3	50
324	Inflammatory Bowel Disease Has a Small Effect on Bone Mineral Density and Risk for Osteoporosis. Clinical Gastroenterology and Hepatology, 2013, 11, 278-285.	4.4	45

#	Article	IF	CITATIONS
325	Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Alimentary Pharmacology and Therapeutics, 2013, 38, 274-283.	3.7	62
326	Physicians' Perceptions of Risks and Practices in Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2013, 58, 46-52.	2.3	43
327	Association between Early Childhood Otitis Media and Pediatric Inflammatory Bowel Disease: An Exploratory Population-Based Analysis. Journal of Pediatrics, 2013, 162, 510-514.	1.8	28
328	Changes in Fatigue Over 2 Years Are Associated With Activity of Inflammatory Bowel Disease and Psychological Factors. Clinical Gastroenterology and Hepatology, 2013, 11, 1140-1146.	4.4	87
329	Inflammatory bowel disease and the risk of osteoporosis and fracture. Maturitas, 2013, 76, 315-319.	2.4	46
330	Geographical variability and environmental risk factors in inflammatory bowel disease. Gut, 2013, 62, 630-649.	12.1	476
331	International variation in medication prescription rates among elderly patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, 878-889.	1.3	61
332	Time to Awaken to Issues of Sleep and Inflammatory Bowel Disease: There Are Many Unanswered Questions. Clinical Gastroenterology and Hepatology, 2013, 11, 972-974.	4.4	0
333	Mo1458 The Incidence of Post ERCP Pancreatitis, Bleeding, Perforation and ERCP Related Mortality, and Clinical Risk Factors for Post ERCP Pancreatitis: a Population Based Study. Gastrointestinal Endoscopy, 2013, 77, AB390.	1.0	Ο
334	Brain-Gut Interactions in Inflammatory Bowel Disease. Gastroenterology, 2013, 144, 36-49.	1.3	512
335	First-degree Relatives of Patients with Rheumatoid Arthritis Exhibit High Prevalence of Joint Symptoms. Journal of Rheumatology, 2013, 40, 818-824.	2.0	34
336	Commentary: predicting complicated Crohn's disease and surgeryÂ-Âphenotypes, genetics, serology and psychological characteristics of a population-based cohort - authors' reply. Alimentary Pharmacology and Therapeutics, 2013, 38, 556-557.	3.7	1
337	The impact of abdominal computed tomography in a tertiary referral centre emergency department on the management of patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2013, 38, 513-521.	3.7	40
338	Inflammatory bowel disease and the risk of fracture after controlling for FRAX. Journal of Bone and Mineral Research, 2013, 28, 1007-1013.	2.8	27
339	The Utility of Screening for Asymptomatic Lower Extremity Deep Venous Thrombosis during Inflammatory Bowel Disease Flares. Inflammatory Bowel Diseases, 2013, 19, 1053-1058.	1.9	16
340	A Review of Mortality and Surgery in Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 1.	1.9	109
341	Patient Satisfaction with the Endoscopy Experience and Willingness to Return in a Central Canadian Health Region. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 259-266.	1.7	27
342	Antibiotic use and the risk of Crohn's disease. Gastroenterology and Hepatology, 2013, 9, 393-5.	0.1	2

#	Article	IF	CITATIONS
343	Pregnancy and the Risk of Rheumatoid Arthritis in a Highly Predisposed North American Native Population. Journal of Rheumatology, 2012, 39, 2253-2260.	2.0	44
344	The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products. Gut, 2012, 61, 521-527.	12.1	56
345	Vitamin D Receptor Polymorphism rs2228570 (Fok1) Is Associated with Rheumatoid Arthritis in North American Natives. Journal of Rheumatology, 2012, 39, 1792-1797.	2.0	47
346	Role of biological therapy for inflammatory bowel disease in developing countries. Gut, 2012, 61, 706-712.	12.1	39
347	Why and Where to Look in the Environment with Regard to the Etiology of Inflammatory Bowel Disease. Digestive Diseases, 2012, 30, 28-32.	1.9	12
348	Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons, and the American Society of Colorectal Surgeons Evidence Based Reviews in Surgery – Colorectal Surgery. Diseases of the Colon and Rectum, 2012, 55, 727-731.	1.3	0
349	Hospitalisations and surgery in Crohn's disease. Gut, 2012, 61, 622-629.	12.1	244
350	69 Trends in Utilization of Diagnostic and Therapeutic Endoscopic Retrograde Cholangiopancreatography (ERCP) in Manitoba: A Population Based Study. Gastrointestinal Endoscopy, 2012, 75, AB120-AB121.	1.0	0
351	Pathological reassessment of hyperplastic colon polyps in a city-wide pathology practice: implications for polyp surveillance recommendations. Gastrointestinal Endoscopy, 2012, 76, 1003-1008.	1.0	56
352	5-Aminosalicylic Acid Is Not Protective Against Colorectal Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Non-Referral Populations. American Journal of Gastroenterology, 2012, 107, 1298-1304.	0.4	91
353	Longitudinal Change in Bone Mineral Density in a Population-Based Cohort of Patients with Inflammatory Bowel Disease. Calcified Tissue International, 2012, 91, 356-363.	3.1	23
354	Oral health in a First Nations and a non-Aboriginal population in Manitoba. International Journal of Circumpolar Health, 2012, 71, 17394.	1.2	10
355	Homocysteinemia and B vitamin status among adult patients with inflammatory bowel disease: A one-year prospective follow-up study. Inflammatory Bowel Diseases, 2012, 18, 718-724.	1.9	33
356	Direct Medical Cost of Managing IBD Patients: A Canadian Population-based Study. Inflammatory Bowel Diseases, 2012, 18, 1498-1508.	1.9	71
357	Integrated Models of Care in Managing Inflammatory Bowel Disease: A Discussion. Inflammatory Bowel Diseases, 2012, 18, 1582-1587.	1.9	51
358	Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: Evidence of gene-gene interactions. Inflammatory Bowel Diseases, 2012, 18, 1591.	1.9	2
359	Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis and Rheumatism, 2012, 64, 1720-1729.	6.7	55
360	Gastrointestinal symptoms before and during menses in women with <scp>IBD</scp> . Alimentary Pharmacology and Therapeutics, 2012, 36, 135-144.	3.7	36

#	Article	IF	CITATIONS
361	Exposure to bisphosphonates and risk of colorectal cancer. Cancer, 2012, 118, 1236-1243.	4.1	23
362	Measures of relative importance for health-related quality of life. Quality of Life Research, 2012, 21, 1-11.	3.1	22
363	Common Symptoms and Stressors Among Individuals With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2011, 9, 769-775.	4.4	86
364	Increased Risk of Nonmelanoma Skin Cancers Among Individuals With Inflammatory Bowel Disease. Gastroenterology, 2011, 141, 1612-1620.	1.3	145
365	The color of the most effective tool to use in dysplasia surveillance in inflammatory bowel disease. Gastrointestinal Endoscopy, 2011, 74, 849-851.	1.0	2
366	Outcomes of Patients With Crohn's Disease Improved From 1988 to 2008 and Were Associated With Increased Specialist Care. Gastroenterology, 2011, 141, 90-97.	1.3	161
367	Association Between the Use of Antibiotics and New Diagnoses of Crohn's Disease and Ulcerative Colitis. American Journal of Gastroenterology, 2011, 106, 2133-2142.	0.4	211
368	Targeting IL-12/IL-23 by Employing a p40 Peptide-Based Vaccine Ameliorates TNBS-Induced Acute and Chronic Murine Colitis. Molecular Medicine, 2011, 17, 646-656.	4.4	39
369	Assessing Inflammatory Bowel Disease-Associated Antibodies in Caucasian and First Nations Cohorts. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 269-273.	1.7	23
370	Non-HLA genes modulate the risk of rheumatoid arthritis associated with HLA-DRB1 in a susceptible North American Native population. Genes and Immunity, 2011, 12, 568-574.	4.1	54
371	Health service utilization in IBD: comparison of self-report and administrative data. BMC Health Services Research, 2011, 11, 137.	2.2	58
372	Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 590-598.	1.9	104
373	Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 1451-1463.	1.9	72
374	Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile. Inflammatory Bowel Diseases, 2011, 17, 1540-1546.	1.9	75
375	Validating Crohn's disease activity indices for use in assessing postoperative recurrence. Inflammatory Bowel Diseases, 2011, 17, 1547-1556.	1.9	44
376	Screening for cervical and breast cancer among women with inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 1741-1750.	1.9	31
377	Distinct and overlapping genetic loci in crohn's disease and ulcerative colitis: Correlations with pathogenesis. Inflammatory Bowel Diseases, 2011, 17, 1936-1942.	1.9	105
378	A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 1882-1889.	1.9	227

#	Article	IF	CITATIONS
379	Summing Up: Quality of Life in Chronic Immune-Mediated Inflammatory Diseases. Journal of rheumatology Supplement, The, 2011, 88, 62-65.	2.2	2
380	Complete Genome Sequence of Adherent Invasive <i>Escherichia coli</i> UM146 Isolated from Ileal Crohn's Disease Biopsy Tissue. Journal of Bacteriology, 2011, 193, 583-583.	2.2	55
381	Psychiatric Disorders in Patients with Immune-Mediated Inflammatory Diseases: Prevalence, Association with Disease Activity, and Overall Patient Well-being. Journal of rheumatology Supplement, The, 2011, 88, 31-35.	2.2	35
382	Fatigue and Quality of Sleep in Patients with Immune-Mediated Inflammatory Disease. Journal of rheumatology Supplement, The, 2011, 88, 36-42.	2.2	18
383	Epidemiologic Clues to Inflammatory Bowel Disease. Current Gastroenterology Reports, 2010, 12, 495-501.	2.5	35
384	AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochemical Pharmacology, 2010, 80, 1708-1717.	4.4	155
385	Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflammatory Bowel Diseases, 2010, 16, 233-242.	1.9	187
386	World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of IBD in 2010. Inflammatory Bowel Diseases, 2010, 16, 112-124.	1.9	393
387	Lessons from geographic mapping of IBD in France. Inflammatory Bowel Diseases, 2010, 16, 804-806.	1.9	3
388	Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflammatory Bowel Diseases, 2010, 16, 962-973.	1.9	113
389	How Well Does the Internet Answer Patients' Questions about Inflammatory Bowel Disease?. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 671-677.	1.7	38
390	Response to Dr Rustagi. American Journal of Gastroenterology, 2010, 105, 2115-2116.	0.4	0
391	Novel Anti-Inflammatory Action of 5-Aminoimidazole-4-carboxamide Ribonucleoside with Protective Effect in Dextran Sulfate Sodium-Induced Acute and Chronic Colitis. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 717-725.	2.5	69
392	Anti–Tumor Necrosis Factor Therapy in Crohn's Disease: More Information and More Questions About the Long Term. Clinical Gastroenterology and Hepatology, 2010, 8, 556-558.	4.4	5
393	A Prospective Population-Based Study of Triggers of Symptomatic Flares in IBD. American Journal of Gastroenterology, 2010, 105, 1994-2002.	0.4	328
394	New Insights into IBD Epidemiology: Are There Any Lessons for Treatment?. Digestive Diseases, 2010, 28, 406-410.	1.9	38
395	Association Between the Use of Antibiotics in the First Year of Life and Pediatric Inflammatory Bowel Disease. American Journal of Gastroenterology, 2010, 105, 2687-2692.	0.4	373
396	Epidemiology of Immune-Mediated Inflammatory Diseases: Incidence, Prevalence, Natural History, and Comorbidities. Journal of rheumatology Supplement, The, 2010, 85, 2-10.	2.2	173

#	Article	IF	CITATIONS
397	Body mass and composition affect bone density in recently diagnosed inflammatory bowel disease: The Manitoba IBD cohort study. Inflammatory Bowel Diseases, 2009, 15, 39-46.	1.9	43
398	Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: A randomized, double-blind, placebo-controlled pilot study. Inflammatory Bowel Diseases, 2009, 15, 17-24.	1.9	218
399	Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management. Inflammatory Bowel Diseases, 2009, 15, 1105-1118.	1.9	480
400	Phylogenetic analysis of inflammatory bowel disease associated Escherichia coli and the fimH virulence determinant. Inflammatory Bowel Diseases, 2009, 15, 1737-1745.	1.9	45
401	Response:. Gastrointestinal Endoscopy, 2009, 69, 390.	1.0	0
402	Colonoscopy and its complications across a Canadian regional health authority. Gastrointestinal Endoscopy, 2009, 69, 665-671.	1.0	100
403	Risk of Cervical Abnormalities in Women With Inflammatory Bowel Disease: A Population-Based Nested Case-Control Study. Gastroenterology, 2009, 136, 451-458.	1.3	116
404	The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity. American Journal of Gastroenterology, 2009, 104, 1754-1763.	0.4	96
405	The evolving epidemiology of inflammatory bowel disease. Current Opinion in Gastroenterology, 2009, 25, 301-305.	2.3	89
406	Population-based controlled study of social support, self-perceived stress, activity and work issues, and access to health care in inflammatory bowel disease. Inflammatory Bowel Diseases, 2008, 14, 526-535.	1.9	49
407	Population-based case-control study of alpha 1-antitrypsin and SLC11A1 in Crohn's disease and ulcerative colitis. Inflammatory Bowel Diseases, 2008, 14, 1112-1117.	1.9	24
408	Assessing environmental risk factors affecting the inflammatory bowel diseases: A joint workshop of the Crohn's & Colitis Foundations of Canada and the USA. Inflammatory Bowel Diseases, 2008, 14, 1139-1146.	1.9	21
409	Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflammatory Bowel Diseases, 2008, 14, 1575-1584.	1.9	205
410	Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: Evidence of gene–gene interactions. Inflammatory Bowel Diseases, 2008, 14, 1528-1541.	1.9	68
411	Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut, 2008, 57, 1185-1191.	12.1	239
412	An SNP linkage scan identifies significant Crohn's disease loci on chromosomes 13q13.3 and, in Jewish families, on 1p35.2 and 3q29. Genes and Immunity, 2008, 9, 161-167.	4.1	10
413	How many duodenal biopsy specimens are required to make a diagnosis of celiac disease?. Gastrointestinal Endoscopy, 2008, 67, 1082-1087.	1.0	174
414	The Incidence of Arterial Thromboembolic Diseases in Inflammatory Bowel Disease: A Population-Based Study. Clinical Gastroenterology and Hepatology, 2008, 6, 41-45.	4.4	202

#	Article	IF	CITATIONS
415	Parathyroid hormone is predictive of low bone mass in Canadian Aboriginal and White women. Bone, 2008, 42, 498-504.	2.9	6
416	The Manitoba IBD Cohort Study: A Population-Based Study of the Prevalence of Lifetime and 12-Month Anxiety and Mood Disorders. American Journal of Gastroenterology, 2008, 103, 1989-1997.	0.4	358
417	Surveillance programmes for colorectal cancer in inflammatory bowel disease: have we got it right?. Gut, 2008, 57, 1194-1196.	12.1	6
418	Testing the Interaction between NOD-2 Status and Serological Response to Mycobacterium paratuberculosis in Cases of Inflammatory Bowel Disease. Journal of Clinical Microbiology, 2007, 45, 968-971.	3.9	28
419	Predictors of Medication Adherence in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2007, 102, 1417-1426.	0.4	234
420	Is hyperhomocysteinemia associated with osteoporosis in patients with Crohn's disease?. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 550-551.	1.7	0
421	Utilization of Health-Care Resources by Patients With IBD in Manitoba: A Profile of Time Since Diagnosis. American Journal of Gastroenterology, 2007, 102, 1683-1691.	0.4	36
422	Response to Wong et al American Journal of Gastroenterology, 2007, 102, 2603-2604.	0.4	0
423	Mutations in Clotting Factors and Inflammatory Bowel Disease. American Journal of Gastroenterology, 2007, 102, 338-343.	0.4	46
424	Nutrition Assessment of Patients With Inflammatory Bowel Disease. Journal of Parenteral and Enteral Nutrition, 2007, 31, 311-319.	2.6	255
425	High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut, 2007, 56, 669-675.	12.1	367
426	A Population-Based Case-Control Study of CARD15 and Other Risk Factors in Crohn's Disease and Ulcerative Colitis. American Journal of Gastroenterology, 2007, 102, 313-323.	0.4	60
427	Hospitalization-Based Major Comorbidity of Inflammatory Bowel Disease in Canada. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 507-511.	1.7	50
428	Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 759-762.	1.9	58
429	Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 675-683.	1.9	198
430	The chromoendoscopy in ulcerative colitis debate. Inflammatory Bowel Diseases, 2007, 13, 1275-1276.	1.9	0
431	Drug therapy for inflammatory bowel disease in pregnancy and the puerperium. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 835-847.	2.4	30
432	A Population-Based Case Control Study of Potential Risk Factors for IBD. American Journal of Gastroenterology, 2006, 101, 993-1002.	0.4	310

#	Article	IF	CITATIONS
433	Natural History and Management of Flat and Polypoid Dysplasia in Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2006, 35, 573-579.	2.2	13
434	Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology, 2006, 4, 325-334.	4.4	165
435	New diagnostic imaging tools for inflammatory bowel disease. Gut, 2006, 55, 733-741.	12.1	86
436	The Relationship of Inflammatory Bowel Disease Type and Activity to Psychological Functioning and Quality of Life. Clinical Gastroenterology and Hepatology, 2006, 4, 1491-1501.e1.	4.4	248
437	Are Perineal and Luminal Fistulas Associated in Crohn's Disease? A Population-Based Study. Clinical Gastroenterology and Hepatology, 2006, 4, 1130-1134.	4.4	152
438	Health Care Resource Utilization in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 731-743.	4.4	75
439	Osteoporosis in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 152-156.	4.4	27
440	The Placebo Effect for Gastroenterology: Tool or Torment. Clinical Gastroenterology and Hepatology, 2006, 4, 1302-1308.	4.4	24
441	Canadian Physicians' Choices for Their Own Colon Cancer Screening. Canadian Journal of Gastroenterology & Hepatology, 2006, 20, 281-284.	1.7	9
442	Neoplasia in inflammatory bowel disease: Surveillance and management strategies. Current Gastroenterology Reports, 2006, 8, 513-518.	2.5	12
443	Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition, 2006, 22, 1210-1213.	2.4	86
444	Risk of Developing Colorectal Cancer Following a Negative Colonoscopy Examination. JAMA - Journal of the American Medical Association, 2006, 295, 2366.	7.4	375
445	Green et al. Respond to "Clues to the Etiology of Inflammatory Bowel Disease― American Journal of Epidemiology, 2006, 164, 627-628.	3.4	1
446	Colorectal Cancer Risk Following a Negative Colonoscopy—Reply. JAMA - Journal of the American Medical Association, 2006, 296, 2436.	7.4	0
447	The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study. American Journal of Gastroenterology, 2006, 101, 1559-1568.	0.4	522
448	A Population-based Ecologic Study of Inflammatory Bowel Disease: Searching for Etiologic Clues. American Journal of Epidemiology, 2006, 164, 615-623.	3.4	128
449	Inflammatory bowel diseases as secondary causes of osteoporosis. Current Osteoporosis Reports, 2006, 4, 116-123.	3.6	3
450	A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Alimentary Pharmacology and Therapeutics, 2005, 21, 373-384.	3.7	34

#	Article	IF	CITATIONS
451	Serum Osteoprotegerin Is Increased in Crohn's Disease: a Population-Based Case Control Study. Inflammatory Bowel Diseases, 2005, 11, 325-330.	1.9	55
452	Crohn's Disease and M. paratuberculosis: Where's the Beef?. Inflammatory Bowel Diseases, 2005, 11, 1025-1027.	1.9	3
453	Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology & Hepatology, 2005, 19, 5A-36A.	1.7	2,711
454	Therapy Insight: osteoporosis in inflammatory bowel disease—advances and retreats. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 232-239.	1.7	16
455	A Prospective Comparison Study of MRI versus Small Bowel Follow-Through in Recurrent Crohn's Disease. American Journal of Gastroenterology, 2005, 100, 2493-2502.	0.4	100
456	Diversity of the Human Intestinal Microbial Flora. Science, 2005, 308, 1635-1638.	12.6	6,617
457	Limiting fracture risk in Crohn's disease: Is there anything better than calcium and vitamin D?. Clinical Gastroenterology and Hepatology, 2005, 3, 110-112.	4.4	6
458	Defining the predictors of the placebo response in irritable bowel syndrome. Clinical Gastroenterology and Hepatology, 2005, 3, 237-247.	4.4	97
459	The Clustering of Other Chronic Inflammatory Diseases in Inflammatory Bowel Disease: A Population-Based Study. Gastroenterology, 2005, 129, 827-836.	1.3	493
460	Complementary and Alternative Medicine Use by Patients with Inflammatory Bowel Disease: Are Canadian Physicians Failing with Conventional Therapy, or Not?. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 47-48.	1.7	5
461	Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. New England Journal of Medicine, 2004, 350, 876-885.	27.0	2,026
462	Detection of Species-Specific Helicobacter Ribosomal DNA in Intestinal Biopsy Samples from a Population-Based Cohort of Patients with Ulcerative Colitis. Journal of Clinical Microbiology, 2004, 42, 660-664.	3.9	28
463	Population-Based Case Control Study of Seroprevalence of <i>Mycobacterium paratuberculosis</i> in Patients with Crohn's Disease and Ulcerative Colitis. Journal of Clinical Microbiology, 2004, 42, 1129-1135.	3.9	110
464	A BALANCING VIEW: Dysplasia Surveillance in Ulcerative Colitis— Sorting the Pro from the Con. American Journal of Gastroenterology, 2004, 99, 1636-1637.	0.4	10
465	Predictors of Alternative and Complementary Medicine Use in Inflammatory Bowel Disease: Do Measures of Conventional Health Care Utilization Relate to Use?. American Journal of Gastroenterology, 2004, 99, 889-893.	0.4	74
466	Osteoporosis and inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2004, 19, 941-952.	3.7	54
467	Antibiotics as a First-line Therapy for Crohn's Disease. Inflammatory Bowel Diseases, 2004, 10, 324-326.	1.9	6
468	Another Look at Fracture Risk in IBD. Inflammatory Bowel Diseases, 2004, 10, 886-887.	1.9	4

#	Article	IF	CITATIONS
469	The Incidence of Helicobacter pylori Acquisition in Children of a Canadian First Nations Community and the Potential for Parent-to-Child Transmission. Helicobacter, 2004, 9, 59-68.	3.5	56
470	CYFIP2 is highly abundant in CD4+ cells from multiple sclerosis patients and is involved in T cell adhesion. European Journal of Immunology, 2004, 34, 1217-1227.	2.9	34
471	Patterns of Colonic Involvement at Initial Presentation in Ulcerative Colitis : A Retrospective Study of 46 Newly Diagnosed Cases. American Journal of Clinical Pathology, 2004, 122, 94-99.	0.7	23
472	Inflammatory bowel diseasehospitalization. Health Reports, 2004, 15, 25-40.	0.8	8
473	Effects of daily, light and moderate-heavy ethanol exposure on extent of hepatic injury and recovery following toxin-induced acute hepatitis in rats. Digestive Diseases and Sciences, 2003, 48, 926-931.	2.3	7
474	Title is missing!. Journal of Clinical Psychology in Medical Settings, 2003, 10, 57-69.	1.4	49
475	Activation and deactivation in blood oxygenation level dependent functional magnetic resonance imaging. Concepts in Magnetic Resonance, 2003, 16A, 63-70.	1.3	22
476	Therapeutic value of a gastroenterology consultation in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2003, 17, 871-880.	3.7	22
477	DO ALL PATIENTS WITH CELIAC DISEASE AND INFLAMMATORY BOWEL DISEASE NEED DUAL-ENERGY X-RAY ABSORPTIOMETRY?. Inflammatory Bowel Diseases, 2003, 9, 70-71.	1.9	Ο
478	Work Losses Related To Inflammatory Bowel Disease in The United States: Results From The National Health Interview Survey. American Journal of Gastroenterology, 2003, 98, 1064-1072.	0.4	165
479	Study of Animal-Borne Infections in the Mucosas of Patients with Inflammatory Bowel Disease and Population-Based Controls. Journal of Clinical Microbiology, 2003, 41, 4986-4990.	3.9	55
480	Work losses related to inflammatory bowel disease in Canada: results from a national population health survey. American Journal of Gastroenterology, 2003, 98, 844-849.	0.4	87
481	Does The Use of 5-Aminosalicylates in Inflammatory Bowel Disease Prevent The Development of Colorectal Cancer?. American Journal of Gastroenterology, 2003, 98, 2784-2788.	0.4	102
482	Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. American Journal of Gastroenterology, 2003, 98, 2468-2473.	0.4	43
483	The association between corticosteroid use and development of fractures among IBD patients in a population-based database. American Journal of Gastroenterology, 2003, 98, 1797-1801.	0.4	60
484	Bone Density in A Population-Based Cohort of Premenopausal Adult Women With Early Onset Inflammatory Bowel Disease. American Journal of Gastroenterology, 2003, 98, 1094-1100.	0.4	48
485	The pathophysiology of bone disease in gastrointestinal disease. European Journal of Gastroenterology and Hepatology, 2003, 15, 857-864.	1.6	108
486	Cortical mapping of visceral pain in patients with GI disorders using functional magnetic resonance imaging. American Journal of Gastroenterology, 2002, 97, 319-327.	0.4	93

#	Article	IF	CITATIONS
487	Generational differences in the age at diagnosis with IBD: genetic anticipation, bias, or temporal effects. American Journal of Gastroenterology, 2002, 97, 636-640.	0.4	29
488	Age at Acquisition of Helicobacter pylori in a Pediatric Canadian First Nations Population. Helicobacter, 2002, 7, 76-85.	3.5	51
489	Osteoporosis and other complications of inflammatory bowel disease. Current Opinion in Gastroenterology, 2002, 18, 428-434.	2.3	21
490	Alteration in Expression of β2 Integrins on Lamina Propria Lymphocytes in Ulcerative Colitis and Crohn's Disease. Clinical Immunology, 2002, 104, 67-72.	3.2	17
491	Treatment of the extraintestinal manifestations of inflammatory bowel disease. Current Gastroenterology Reports, 2002, 4, 513-516.	2.5	21
492	Infliximab as First-Line Therapy for Crohn's Disease. Inflammatory Bowel Diseases, 2002, 8, 63-65.	1.9	1
493	Cancer Prevention in Inflammatory Bowel Disease and the Chemoprophylactic Potential of 5-Aminosalicylic Acid. Inflammatory Bowel Diseases, 2002, 8, 356-361.	1.9	62
494	Usage of supplemental alternative medicine by community-based patients with gastroesophageal reflux disease (GERD). Digestive Diseases and Sciences, 2002, 47, 1-8.	2.3	16
495	The relationship between inflammatory bowel disease and socioeconomic variables. American Journal of Gastroenterology, 2001, 96, 2117-2125.	0.4	124
496	The Incidence of Deep Venous Thrombosis and Pulmonary Embolism among Patients with Inflammatory Bowel Disease: A Population-based Cohort Study. Thrombosis and Haemostasis, 2001, 85, 430-434.	3.4	517
497	Extraintestinal manifestations of inflammatory bowel disease. Current Gastroenterology Reports, 2001, 3, 477-483.	2.5	40
498	Cancer risk in patients with inflammatory bowel disease. Cancer, 2001, 91, 854-862.	4.1	1,090
499	All Patients with Inflammatory Bowel Disease Should Have Bone Density Assessment. Inflammatory Bowel Diseases, 2001, 7, 168-169.	1.9	1
500	Does gastroenterology consultation change management of patients receiving hematopoietic stem cell transplantation?. Bone Marrow Transplantation, 2001, 28, 289-294.	2.4	24
501	Novel therapeutics in inflammatory bowel disease. Expert Opinion on Therapeutic Patents, 2001, 11, 1081-1096.	5.0	3
502	The Use of 1H Magnetic Resonance Spectroscopy in Inflammatory Bowel Diseases: Distinguishing Ulcerative Colitis From Crohn's Disease. American Journal of Gastroenterology, 2001, 96, 442-448.	0.4	59
503	Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study. American Journal of Gastroenterology, 2001, 96, 3348-3355.	0.4	37
504	The Prevalence of Extraintestinal Diseases in Inflammatory Bowel Disease: A Population-Based Study. American Journal of Gastroenterology, 2001, 96, 1116-1122.	0.4	636

#	Article	IF	CITATIONS
505	Small-area Variations and Sociodemographic Correlates for the Incidence of Crohn's Disease and Ulcerative Colitis. American Journal of Epidemiology, 2001, 154, 328-335.	3.4	135
506	Cancer risk in patients with inflammatory bowel disease. , 2001, 91, 854.		4
507	The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thrombosis and Haemostasis, 2001, 85, 430-4.	3.4	164
508	The Incidence of Fracture among Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study. Annals of Internal Medicine, 2000, 133, 795.	3.9	411
509	Is Infliximab the Drug We Have Been Waiting For in Crohn's Disease?. Inflammatory Bowel Diseases, 2000, 6, 140-141.	1.9	Ο
510	Viruses and Inflammatory Bowel Disease: Is There Evidence for a Causal Association?. Inflammatory Bowel Diseases, 2000, 6, 34-39.	1.9	9
511	Neoplastic and other complications of inflammatory bowel disease. Current Gastroenterology Reports, 2000, 2, 451-459.	2.5	6
512	Perceptual responses in patients with inflammatory and functional bowel disease. Gut, 2000, 47, 497-505.	12.1	171
513	Clinically Significant Gastrointestinal Bleeding in Critically III Patients in An Era of Prophylaxis. American Journal of Gastroenterology, 2000, 95, 2801-2806.	0.4	58
514	Direct hospital costs for patients with inflammatory bowel disease in a Canadian Tertiary Care University Hospital. American Journal of Gastroenterology, 2000, 95, 677-683.	0.4	99
515	Colonoscopy plus biopsy in the inflammatory bowel diseases. Gastrointestinal Endoscopy Clinics of North America, 2000, 10, 755-74.	1.4	2
516	Crohn's Disease and the Melkersson-Rosenthal Syndrome. Canadian Journal of Gastroenterology & Hepatology, 1999, 13, 152-155.	1.7	15
517	Epidemiology of Crohn's Disease and Ulcerative Colitis in a Central Canadian Province: A Population-based Study. American Journal of Epidemiology, 1999, 149, 916-924.	3.4	609
518	The Effects of Physical Exercise on Patients With Crohn's Disease. American Journal of Gastroenterology, 1999, 94, 697-703.	0.4	112
519	An International Survey of The Use and Attitudes Regarding Alternative Medicine by Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 1999, 94, 1298-1303.	0.4	117
520	Helicobacter Pylori in The Canadian Arctic: Seroprevalence and Detection in Community Water Samples. American Journal of Gastroenterology, 1999, 94, 1823-1829.	0.4	72
521	Perianal Crohn's Disease and Pregnancy: Role of The Mode of Delivery. American Journal of Gastroenterology, 1999, 94, 3274-3278.	0.4	137
522	Seroprevalence of Helicobacter pylori, incidence of gastric cancer, and peptic ulcer-associated hospitalizations in a Canadian Indian population. Digestive Diseases and Sciences, 1999, 44, 668-674.	2.3	46

#	Article	IF	CITATIONS
523	Extracorporeal shock wave lithotripsy causing colonic injury. Digestive Diseases and Sciences, 1999, 44, 2485-2487.	2.3	17
524	Cancer surveillance in inflammatory bowel disease. Current Gastroenterology Reports, 1999, 1, 496-504.	2.5	15
525	A NOVEL APPROACH TO THE STICKY BUSINESS OF CROHN'S DISEASE THERAPY. Inflammatory Bowel Diseases, 1999, 5, 235-236.	1.9	0
526	Placebos in medicine. Seminars in Gastrointestinal Disease, 1999, 10, 3-7.	0.8	6
527	β2 Integrin/ICAM Expression in Crohn's Disease. Clinical Immunology and Immunopathology, 1998, 86, 147-160.	2.0	73
528	How do we assess the value of surveillance techniques in ulcerative colitis?. Journal of Gastrointestinal Surgery, 1998, 2, 318-321.	1.7	8
529	Challenges in Designing a Randomized Trial of Surveillance Colonoscopy in IBD. Inflammatory Bowel Diseases, 1998, 4, 132-141.	1.9	14
530	Comparison of Salivary and Serum Enzyme Immunoassays for the Diagnosis ofHelicobacter pyloriInfection. Canadian Journal of Infectious Diseases & Medical Microbiology, 1998, 9, 277-280.	0.3	1
531	Infectious Mononucleosis Presenting with Cholestatic Liver Disease. Annals of Internal Medicine, 1998, 128, 509.	3.9	23
532	Primary Adrenal Lymphoma Associated with Adrenal Insufficiency: A Distinct Clinical Entity. Leukemia and Lymphoma, 1997, 24, 363-367.	1.3	46
533	A prospective randomized comparison between small bowel enteroclysis and small bowel follow-through in Crohn's disease. Gastroenterology, 1997, 113, 390-398.	1.3	129
534	The diagnostic yield of lower endoscopy plus biopsy in nonbloody diarrhea. Gastrointestinal Endoscopy, 1997, 46, 338-343.	1.0	46
535	Peripheral blood lymphocyte beta 2 integrin and ICAM expression in inflammatory bowel disease. Digestive Diseases and Sciences, 1997, 42, 2338-2349.	2.3	19
536	Characterization of afferent mechanisms in ileoanal pouches. American Journal of Gastroenterology, 1997, 92, 103-8.	0.4	20
537	On making the diagnosis of ulcerative colitis. American Journal of Gastroenterology, 1997, 92, 1247-52.	0.4	4
538	The Differential Expression of a Novel Intestinal Epithelial Glycoprotein in Various Forms of Inflammatory Bowel Disease. American Journal of Clinical Pathology, 1996, 106, 42-51.	0.7	3
539	A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Alimentary Pharmacology and Therapeutics, 1996, 10, 777-786.	3.7	142
540	Diagnostic potential for cancer via 1H magnetic resonance spectroscopy of colon tissue. Anticancer Research, 1996, 16, 1553-8.	1.1	26

#	Article	IF	CITATIONS
541	Critical appraisal of enteral nutrition as primary therapy in adults with Crohn's disease. American Journal of Gastroenterology, 1996, 91, 2075-9.	0.4	10
542	Beta 2-integrin/intercellular adhesion molecule (ICAM) expression in the normal human intestine. Clinical and Experimental Immunology, 1996, 106, 160-9.	2.6	17
543	Small Bowel Transplantation. Scandinavian Journal of Gastroenterology, 1995, 30, 118-124.	1.5	0
544	Patchiness of mucosal inflammation in treated ulcerative colitis: A prospective study. Gastrointestinal Endoscopy, 1995, 42, 232-237.	1.0	204
545	Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. Journal of Bone and Mineral Research, 1995, 10, 250-256.	2.8	187
546	Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. American Journal of Gastroenterology, 1995, 90, 2106-14.	0.4	113
547	Isolation, identification, and culture of normal mouse colonic glia. Clia, 1994, 12, 108-116.	4.9	27
548	Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Digestive Diseases and Sciences, 1994, 39, 1638-1641.	2.3	35
549	Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet, The, 1994, 343, 71-74.	13.7	587
550	Immunosuppressive and Immunomodulatory Therapy for Inflammatory Bowel Disease. Canadian Journal of Gastroenterology & Hepatology, 1993, 7, 115-120.	1.7	3
551	Achalasia and development of benign esophagobronchial fistula. Digestive Diseases and Sciences, 1992, 37, 609-612.	2.3	8
552	Viruses and inflammatory bowel disease: Is there evidence for a causal association?. Inflammatory Bowel Diseases, 0, 6, 34-39.	1.9	0